Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments Wages, Salaries and Other

Ratios

Protara Therapeutics (TARA) Shares Repurchased (2021 - 2026)

Protara Therapeutics' Shares Repurchased history spans 6 years, with the latest figure at $317000.0 for Q1 2026.

Quarterly Shares Repurchased rose 161.98% to $317000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $881000.0 through Mar 2026, up 95.78% year-over-year, with the annual reading at $685000.0 for FY2025, 42.71% up from the prior year.
Shares Repurchased came in at $317000.0 for Q1 2026, up from $201000.0 in the prior quarter.
In the past five years, Shares Repurchased ranged from a high of $1.1 million in Q4 2023 to a low of $18000.0 in Q3 2022.
The 5-year median for Shares Repurchased is $167000.0 (2025), against an average of $240266.7.
Year-over-year, Shares Repurchased soared 1427.78% in 2023 and then crashed 90.24% in 2024.
Protara Therapeutics' Shares Repurchased stood at $18000.0 in 2022, then surged by 6105.56% to $1.1 million in 2023, then plummeted by 90.24% to $109000.0 in 2024, then soared by 84.4% to $201000.0 in 2025, then soared by 57.71% to $317000.0 in 2026.
Per Business Quant, the three most recent readings for TARA's Shares Repurchased are $317000.0 (Q1 2026), $201000.0 (Q4 2025), and $196000.0 (Q3 2025).